Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

Completed · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia

In brief

The purpose of this study is to see at what dose MDX-1342, a monoclonal antibody, is safe and tolerable for patients with chronic lymphocytic leukemia (CLL). Information on any responses that patients may have to the drug will also be collected.

Key facts

Study ID

NCT00593944

Run by

Bristol-Myers Squibb

People needed

15

Starts

2008-08-01

Expected to finish

2010-05-01

Last updated by the study team

2013-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• relapsed/refractory CD19-positive CLL
• At least 28 days since prior treatment for CLL
• ECOG PS 0-2
• Screening laboratory values must be met

You may not qualify if…

• No prior anti-CD19 antibody tx
• No active, uncontrolled infection
• No prior allogeneic bone marrow transplant
• No autoimmune disease

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Oncology Consultants, PA — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.